ARQT · Stage, GEX levels and seasonality
Arcutis Biotherapeutics, Inc. Common Stock (ARQT)
Last close $28.82 (-0.96%) on 2026-10-16
No card. The trial ends after 7 days unless you choose a paid plan. There is no automatic charge.
Open the chartWeinstein stage
Stage 3A — Topping · 30 weeks in this stage · 30-week average $24.70
Stage 3 (topping): the advance stalls and the 30-week average flattens.
What would change it: Stage 4 begins on a weekly close below 19.3 (the top's support) under a flat or falling 30-week SMA.
GEX levels
Call wall, put wall and gamma flip for ARQT are on Signa plans. What GEX levels tell you.
Seasonality
| Month | Average return | Months up | Years |
|---|---|---|---|
| January | +19.65% | 50% | 4 |
| February | +24.22% | 75% | 4 |
| March | -12.46% | 25% | 4 |
| April | +2.21% | 50% | 4 |
| May | -14.7% | 25% | 4 |
| June | +13.43% | 100% | 4 |
| July | +2.52% | 75% | 4 |
| August | +1.59% | 50% | 4 |
| September | -3.75% | 50% | 4 |
| October (this month) | -13.49% | 33% | 3 |
| November | +17.69% | 67% | 3 |
| December | +23.01% | 67% | 3 |
Based on up to 4 years of weekly closes. Past seasonality does not predict future returns.
On Signa plans
The Signa score and Action Card for ARQT, live options flow, dark pool prints, today's GEX levels with vanna and charm, and what 40+ AI agents say about it.
No card. The trial ends after 7 days unless you choose a paid plan. There is no automatic charge.
Questions about ARQT
What Weinstein stage is ARQT in?
ARQT is in Stage 3A — Topping, for 30 weeks, based on completed weekly bars and its 30-week moving average (24.70).
How has ARQT done in October?
Over the last 3 years, ARQT averaged -13.49% in October and rose in 33% of them. Past seasonality does not predict future returns.
Educational content only, not financial advice. Trading involves substantial risk.